Cargando…
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651018/ https://www.ncbi.nlm.nih.gov/pubmed/26234467 http://dx.doi.org/10.1089/aid.2015.0034 |
_version_ | 1782401598542053376 |
---|---|
author | Karasavvas, Nicos Karnasuta, Chitraporn Savadsuk, Hathairat Madnote, Sirinan Inthawong, Dutsadee Chantakulkij, Somsak Rittiroongrad, Surawach Nitayaphan, Sorachai Pitisuttithum, Punnee Thongcharoen, Prasert Siriyanon, Vinai Andrews, Charla A. Barnett, Susan W. Tartaglia, James Sinangil, Faruk Francis, Donald P. Robb, Merlin L. Michael, Nelson L. Ngauy, Viseth de Souza, Mark S. Paris, Robert M. Excler, Jean-Louis Kim, Jerome H. O'Connell, Robert J. |
author_facet | Karasavvas, Nicos Karnasuta, Chitraporn Savadsuk, Hathairat Madnote, Sirinan Inthawong, Dutsadee Chantakulkij, Somsak Rittiroongrad, Surawach Nitayaphan, Sorachai Pitisuttithum, Punnee Thongcharoen, Prasert Siriyanon, Vinai Andrews, Charla A. Barnett, Susan W. Tartaglia, James Sinangil, Faruk Francis, Donald P. Robb, Merlin L. Michael, Nelson L. Ngauy, Viseth de Souza, Mark S. Paris, Robert M. Excler, Jean-Louis Kim, Jerome H. O'Connell, Robert J. |
author_sort | Karasavvas, Nicos |
collection | PubMed |
description | RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2 and gp120CM235 in MF59 (RV132) at 3 and 6 months. We assessed ELISA binding antibodies to the envelope proteins (Env) 92TH023, A244gD and MNgD, cyclicV2, and gp70V1V2 CaseA2 (subtype B) and 92TH023 (subtype CRF01_AE), and Env-specific IgG1 and IgG3. Antibody responses to gp120 A244gD, MNgD, and gp70V1V2 92TH023 scaffold were significantly higher in RV135 than in RV132. Antibodies to gp70V1V2 CaseA2 were detected only in RV135 vaccine recipients and IgG1 and IgG3 antibody responses to A244gD were significantly higher in RV135. IgG binding to gp70V1V2 CaseA2 and CRF01_AE scaffolds was higher with the AIDSVAX(®)B/E boost but both trials showed similar rates of antibody decline post-vaccination. MF59 did not result in higher IgG antibody responses compared to alum with the antigens tested. However, notable differences in the structure of the recombinant proteins and dosage used for immunizations may have contributed to the magnitude and specificity of IgG induced by the two trials. |
format | Online Article Text |
id | pubmed-4651018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46510182015-12-02 IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens Karasavvas, Nicos Karnasuta, Chitraporn Savadsuk, Hathairat Madnote, Sirinan Inthawong, Dutsadee Chantakulkij, Somsak Rittiroongrad, Surawach Nitayaphan, Sorachai Pitisuttithum, Punnee Thongcharoen, Prasert Siriyanon, Vinai Andrews, Charla A. Barnett, Susan W. Tartaglia, James Sinangil, Faruk Francis, Donald P. Robb, Merlin L. Michael, Nelson L. Ngauy, Viseth de Souza, Mark S. Paris, Robert M. Excler, Jean-Louis Kim, Jerome H. O'Connell, Robert J. AIDS Res Hum Retroviruses Vaccines RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2 and gp120CM235 in MF59 (RV132) at 3 and 6 months. We assessed ELISA binding antibodies to the envelope proteins (Env) 92TH023, A244gD and MNgD, cyclicV2, and gp70V1V2 CaseA2 (subtype B) and 92TH023 (subtype CRF01_AE), and Env-specific IgG1 and IgG3. Antibody responses to gp120 A244gD, MNgD, and gp70V1V2 92TH023 scaffold were significantly higher in RV135 than in RV132. Antibodies to gp70V1V2 CaseA2 were detected only in RV135 vaccine recipients and IgG1 and IgG3 antibody responses to A244gD were significantly higher in RV135. IgG binding to gp70V1V2 CaseA2 and CRF01_AE scaffolds was higher with the AIDSVAX(®)B/E boost but both trials showed similar rates of antibody decline post-vaccination. MF59 did not result in higher IgG antibody responses compared to alum with the antigens tested. However, notable differences in the structure of the recombinant proteins and dosage used for immunizations may have contributed to the magnitude and specificity of IgG induced by the two trials. Mary Ann Liebert, Inc. 2015-11-01 /pmc/articles/PMC4651018/ /pubmed/26234467 http://dx.doi.org/10.1089/aid.2015.0034 Text en © Nicos Karasavvas et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Vaccines Karasavvas, Nicos Karnasuta, Chitraporn Savadsuk, Hathairat Madnote, Sirinan Inthawong, Dutsadee Chantakulkij, Somsak Rittiroongrad, Surawach Nitayaphan, Sorachai Pitisuttithum, Punnee Thongcharoen, Prasert Siriyanon, Vinai Andrews, Charla A. Barnett, Susan W. Tartaglia, James Sinangil, Faruk Francis, Donald P. Robb, Merlin L. Michael, Nelson L. Ngauy, Viseth de Souza, Mark S. Paris, Robert M. Excler, Jean-Louis Kim, Jerome H. O'Connell, Robert J. IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens |
title | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens |
title_full | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens |
title_fullStr | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens |
title_full_unstemmed | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens |
title_short | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens |
title_sort | igg antibody responses to recombinant gp120 proteins, gp70v1/v2 scaffolds, and a cyclicv2 peptide in thai phase i/ii vaccine trials using different vaccine regimens |
topic | Vaccines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651018/ https://www.ncbi.nlm.nih.gov/pubmed/26234467 http://dx.doi.org/10.1089/aid.2015.0034 |
work_keys_str_mv | AT karasavvasnicos iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT karnasutachitraporn iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT savadsukhathairat iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT madnotesirinan iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT inthawongdutsadee iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT chantakulkijsomsak iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT rittiroongradsurawach iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT nitayaphansorachai iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT pitisuttithumpunnee iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT thongcharoenprasert iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT siriyanonvinai iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT andrewscharlaa iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT barnettsusanw iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT tartagliajames iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT sinangilfaruk iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT francisdonaldp iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT robbmerlinl iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT michaelnelsonl iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT ngauyviseth iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT desouzamarks iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT parisrobertm iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT exclerjeanlouis iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT kimjeromeh iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens AT oconnellrobertj iggantibodyresponsestorecombinantgp120proteinsgp70v1v2scaffoldsandacyclicv2peptideinthaiphaseiiivaccinetrialsusingdifferentvaccineregimens |